Asbury Park Press NJ : declared in Asbury drug deals explained in Dead End trial
THOMAS P. COSTELLO 1 of 9 Skip in Skip x Embed x Share CLOSE ASBURY PARK COP ON TRIAL FOR ALLEGED TIES TO GANGS HIV threats heard during 'Dead End' trial | 1:09 Testimony during the 'Dead End' trial states that former Asbury Park cop Keith German was behind false claims that Dorothy Brown was HIV positive. (Photo: Tanya Breen)Buy PhotoFREEHOLD - Testimony at the "Operation Dead End" trial Thursday steered away from claims of crooked behavior by a cop to phone recordings of alleged drug deals. The phone calls were intercepted between early December 2013 and early February 2014 during the "Operation Dead End" wiretap investigation into gang activity in Asbury Park. Doug Hood 8 of 9 Skip in Skip x Embed x Share CLOSE ASBURY PARK COP ON TRIAL FOR ALLEGED TIES TO GANGS Limits on 'Dead End' trial coverage discussed | 5:24 The Monmouth County Prosecutors office is seeking to limit coverage of the 'Dead End' trial to protect the security of witnesses and conduct a fair trial. Doug Hood 7 of 9 Skip in Skip x Embed x Share CLOSE ASBURY PARK COP ON TRIAL FOR ALLEGED TIES TO GANGS Asbury Park cop on trial | 2:57 Prosecutors open their case against an Asbury Park police officer who turned the city into a 'war zone' while working with alleged gang members.
At 10:43 a.m., AstraZeneca facebook/" target="_blank">shares on the New York Stock Exchange were trading at $28.70, down about $5.24 a share (-15.4%). Shares in Anglo-Swedish drugmaker AstraZeneca plunged as much as 17 percent Thursday after a new lung cancer treatment proved less successful than the company had hoped. AstraZeneca said human trials of the drug Imfinzi failed to meet the goal of improving progression-free survival rates in patients with non-small cell lung cancer. (Photo: Christopher Furlong, Getty Images)LONDON — Shares in Anglo-Swedish drugmaker AstraZeneca plunged as much as 17% Thursday after a new lung cancer treatment proved less successful than the company had hoped. The trial will continue to assess overall survival of patients treated with Imfinzi alone and the Imfinzi-tremelimumab combination, AstraZeneca said.
collected by :Lucy William
AstraZeneca's Mystic cancer drug trial fails
The trial, dubbed Mystic, centered on the combination of two immuno-oncology drugs, which are designed to boost the immune system's ability to eradicate cancer cells. AstraZeneca said the combination was no better than standard chemotherapy at shrinking tumors in advanced lung cancer. Analysts had expected net profit of $450 million on revenue of $5.05 billion. The company posted net profit of $477 million, compared with a net loss of $3 million a year earlier, when AstraZeneca took a restructuring charge related to job cuts. It is possible for a treatment to extend overall survival without improving progression-free survival because it may do so without shrinking tumors.At 10:43 a.m., AstraZeneca facebook/" target="_blank">shares on the New York Stock Exchange were trading at $28.70, down about $5.24 a share (-15.4%). Shares in Anglo-Swedish drugmaker AstraZeneca plunged as much as 17 percent Thursday after a new lung cancer treatment proved less successful than the company had hoped. AstraZeneca said human trials of the drug Imfinzi failed to meet the goal of improving progression-free survival rates in patients with non-small cell lung cancer. (Photo: Christopher Furlong, Getty Images)LONDON — Shares in Anglo-Swedish drugmaker AstraZeneca plunged as much as 17% Thursday after a new lung cancer treatment proved less successful than the company had hoped. The trial will continue to assess overall survival of patients treated with Imfinzi alone and the Imfinzi-tremelimumab combination, AstraZeneca said.
collected by :Lucy William
Comments
Post a Comment